Alyson Haslam

3.7k total citations · 1 hit paper
117 papers, 2.3k citations indexed

About

Alyson Haslam is a scholar working on Economics and Econometrics, Oncology and Cancer Research. According to data from OpenAlex, Alyson Haslam has authored 117 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Economics and Econometrics, 34 papers in Oncology and 20 papers in Cancer Research. Recurrent topics in Alyson Haslam's work include Health Systems, Economic Evaluations, Quality of Life (28 papers), Economic and Financial Impacts of Cancer (27 papers) and Cancer Genomics and Diagnostics (17 papers). Alyson Haslam is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (28 papers), Economic and Financial Impacts of Cancer (27 papers) and Cancer Genomics and Diagnostics (17 papers). Alyson Haslam collaborates with scholars based in United States, Switzerland and United Kingdom. Alyson Haslam's co-authors include Vinay Prasad, Jennifer Gill, Timothée Olivier, Spencer Phillips Hey, Emerson Y. Chen, Minki Kim, Sara Wagner Robb, Myung Sun Kim, Mark H. Ebell and James R. Hébert and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Alyson Haslam

103 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

2019 956 citations Alyson Haslam, Vinay Prasad JAMA Network Open profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alyson Haslam United States	18	1.2k	509	368	353	322	117	2.3k
Francesco Pignatti Netherlands	28	854 0.7×	167 0.3×	612 1.7×	479 1.4×	527 1.6×	102	2.8k
Benoît You France	33	1.3k 1.1×	227 0.4×	578 1.6×	462 1.3×	209 0.6×	231	3.3k
Alexandru Eniu Romania	29	2.6k 2.2×	339 0.7×	469 1.3×	344 1.0×	581 1.8×	74	3.7k
Esther Oomen‐de Hoop Netherlands	25	619 0.5×	118 0.2×	523 1.4×	289 0.8×	105 0.3×	124	2.0k
Benjamin Kasenda Switzerland	25	564 0.5×	189 0.4×	210 0.6×	208 0.6×	207 0.6×	64	1.9k
Jessica K. Paulus United States	24	547 0.5×	134 0.3×	214 0.6×	678 1.9×	259 0.8×	70	2.5k
Pavlos Msaouel United States	31	1.1k 0.9×	237 0.5×	1.1k 3.1×	989 2.8×	147 0.5×	225	3.4k
Robert C. Kane United States	22	1.1k 1.0×	268 0.5×	434 1.2×	1.4k 3.9×	87 0.3×	32	3.0k
Gennaro Daniele Italy	24	970 0.8×	101 0.2×	577 1.6×	559 1.6×	171 0.5×	100	1.9k
Chan Zeng United States	27	423 0.4×	276 0.5×	332 0.9×	748 2.1×	162 0.5×	63	2.4k

Countries citing papers authored by Alyson Haslam

Since Specialization

Citations

This map shows the geographic impact of Alyson Haslam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alyson Haslam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alyson Haslam more than expected).

Fields of papers citing papers by Alyson Haslam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alyson Haslam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alyson Haslam. The network helps show where Alyson Haslam may publish in the future.

Co-authorship network of co-authors of Alyson Haslam

This figure shows the co-authorship network connecting the top 25 collaborators of Alyson Haslam. A scholar is included among the top collaborators of Alyson Haslam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alyson Haslam. Alyson Haslam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Veer, Palak Shah, Alyson Haslam, et al.. (2025). Therapeutic anti-cancer vaccines: a systematic review of prospective intervention trials for common hematological malignancies. EClinicalMedicine. 86. 103378–103378.

Duncan, Jacob, Brooke M. Gardner, Ryan Ottwell, et al.. (2025). Assessing patient risk, benefit, and outcomes in drug development: a decade of vemurafenib clinical trials. PubMed. 12(1). 2463830–2463830.

Olivier, Timothée, Alyson Haslam, & Vinay Prasad. (2024). Health-related quality of life in trials with high rates of early censoring: Caution advised. European Journal of Cancer. 205. 114105–114105. 4 indexed citations

Miller, Sarah, Alyson Haslam, & Vinay Prasad. (2024). Financial conflicts of interest among presenters, panellists and moderators at haematology and oncology FDA workshops. European Journal of Clinical Investigation. 54(6). e14184–e14184. 1 indexed citations

Olivier, Timothée, et al.. (2024). Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more. SHILAP Revista de lepidopterología. 3(1). e000364–e000364. 1 indexed citations

Benjamin, David J., Alyson Haslam, & Vinay Prasad. (2024). Cardiovascular/anti‐inflammatory drugs repurposed for treating or preventing cancer: A systematic review and meta‐analysis of randomized trials. Cancer Medicine. 13(5). e7049–e7049. 15 indexed citations

Haslam, Alyson & Vinay Prasad. (2024). Long COVID clinics and services offered by top US hospitals: an empirical analysis of clinical options as of May 2023. BMC Health Services Research. 24(1). 684–684. 2 indexed citations

Haslam, Alyson, et al.. (2023). The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review. Journal of Cancer Research and Clinical Oncology. 149(10). 7355–7362. 4 indexed citations

Haslam, Alyson, Timothée Olivier, & Vinay Prasad. (2023). The definition of long COVID used in interventional studies. European Journal of Clinical Investigation. 53(8). e13989–e13989. 17 indexed citations

10.

Haslam, Alyson, et al.. (2023). Systematic Review and Meta-Analysis of Randomized Trials Testing Interventions to Reduce Physician Burnout. The American Journal of Medicine. 137(3). 249–257.e1. 16 indexed citations

11.

Olivier, Timothée, et al.. (2023). Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity. JAMA Network Open. 6(10). e2338612–e2338612. 13 indexed citations

12.

Haslam, Alyson, et al.. (2023). Frequency and Characteristics of Trials Using Medical Writer Support in High-Impact Oncology Journals. JAMA Network Open. 6(2). e2254405–e2254405. 3 indexed citations

13.

Olivier, Timothée, Claire E.P. Smith, Alyson Haslam, Alfredo Addeo, & Vinay Prasad. (2023). Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022. Journal of Cancer Policy. 37. 100426–100426. 3 indexed citations

14.

Haslam, Alyson, et al.. (2022). Impact of a Farm-to-School Nutrition and Gardening Intervention for Native American Families from the FRESH Study: A Randomized Wait-List Controlled Trial. Nutrients. 14(13). 2601–2601. 19 indexed citations

15.

Benjamin, David J., et al.. (2022). Targeted therapy in lung cancer: Are we closing the gap in years of life lost?. Cancer Medicine. 11(18). 3417–3424. 9 indexed citations

16.

Sborov, Douglas W., Brian McClune, Vinay Prasad, et al.. (2022). Time‐to‐event surrogate end‐points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis. British Journal of Haematology. 200(5). 587–594. 10 indexed citations

17.

Jenei, Kristina, Alyson Haslam, Timothée Olivier, Miloš D. Miljković, & Vinay Prasad. (2022). What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020). BMJ Open. 12(10). e064458–e064458. 5 indexed citations

18.

Haslam, Alyson, et al.. (2022). Evaluating management of progressive disease for control arm patients in trials of first line PD-1 or PD-L1 inhibitor-based treatment for metastatic solid tumours. European Journal of Cancer. 164. 95–104.

19.

Haslam, Alyson, et al.. (2022). Characteristics of oncology podcasts: Attitudes, speakers, conflicts. Journal of Cancer Policy. 32. 100329–100329. 9 indexed citations

20.

Haslam, Alyson, Sara Wagner Robb, Matthew R. Bonner, et al.. (2015). Polychlorinated biphenyls and omega-3 fatty acid exposure from fish consumption, and thyroid cancer among New York anglers. Journal of Environmental Sciences. 41. 270–277. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact